Nuclein, LLC was founded in 2017 by experienced biotechnology entrepreneurs Alan Blake and Dr. Richard Crockett. The company’s mission has been to create a hand-held, disposable, all-in-one, self-test for infectious disease testing, which delivers battery-powered, sample-to-answer results within one hour, without the need to mail in a sample.
The company is headquartered in Austin, Texas.
Mr. Alan Blake is Chief Executive Officer of Nuclein. Prior to his involvement with Nuclein, Mr. Blake was a Co-Founder and CEO of Yorktown Technologies LP, which developed and marketed GloFish®, the world’s first widely commercialized biotech animal. Over the past 17 years, GloFish grew to become the most visible consumer biotech product in the world, available in more than 7,000 retail locations, including Walmart, PetSmart and Petco. GloFish was sold to Spectrum Brands Inc. (NYSE: SPB) in 2017. Before GloFish, Mr. Blake founded and led ClassMap, a venture capitalist funded startup in the online learning space, managing the daily operations of 50 employees. Mr. Blake has also served as a Board Member for numerous companies and nonprofit organizations. He graduated with highest honors from the University of Texas at Austin with a Bachelor of Business Administration in finance and holds 22 patents.
Dr. Richard Crockett
Dr. Richard Crockett is President of Nuclein. Prior to Nuclein, Dr. Crockett was Co-Founder and President of Yorktown Technologies LP, leading the research, development, production and regulatory efforts of the company, including the successful review of multiple FDA applications. Beyond Yorktown, Dr. Crockett is an experienced entrepreneur, who prior to co-founding Yorktown Technologies, co-founded ClassMap with Mr. Blake. He graduated from Yale University with a Bachelor of Science in molecular, cellular and developmental biology, later returning to Yale to earn his medical doctorate before surgical residency at Mt. Sinai Hospital in New York. Dr. Crockett holds 19 patents and is published in several peer-reviewed journals.
Nuclein was founded in 2017 by experienced biotechnology entrepreneurs Alan Blake and Dr. Richard Crockett.
Board of Directors
Dr. John Butler
Dr. John Butler is the Director of the Herb Kelleher Center for Entrepreneurship at the University of Texas at Austin’s McCombs School of Business. He is also a former Director of UT Austin’s IC2 Institute (2002-2013), which has produced more than 250 companies and helped them to collectively raise roughly $1 billion. In addition to serving on multiple other boards, Dr. Butler is a former Board Manager of GloFish LLC, the General Partner of Yorktown Technologies LP, and a noted author in the area of entrepreneurship. Among other career highlights, he was appointed by President George W. Bush to the J. William Fulbright Scholarship Board in 2006 and 2007. Dr. Butler holds a Bachelor of Arts from Louisiana State University and a doctorate in sociology from Northwestern University.
Mr. Sanjay Chandra is a Principal at Trinity Private Equity Group, managing more than $2.5 billion in assets and serves its affiliated companies in a variety of roles and responsibilities. In addition, Mr. Chandra is a Co-Founder and Vice Chairman of American Leather, a former Board Manager of GloFish LLC, and a Board Member of numerous other companies. Mr. Chandra also serves as an Engineering Advisory Board Member for the Cockrell School of Engineering at the University of Texas at Austin. Mr. Chandra graduated with highest honors from UT Austin with a Bachelor of Science in electrical and computer engineering and is a CFA charterholder.
Nuclein’s board of directors has decades of experience leading diverse organizations including technology, research, academics, and medical device manufacturing.
Dr. William Cunningham
Dr. William Cunningham holds the James L. Bayless Chair in Free Enterprise at the University of Texas at Austin. He currently teaches corporate governance at the University of Texas at Austin School of Law and the McCombs School of Business. Dr. Cunningham previously served as President of UT Austin (1985-1992) and Chancellor of the University of Texas System (1992-2000). In addition to serving on many public commissions and nonprofit boards, he has been a Board Member of numerous public companies, including currently serving as Chairman of the Board of Lincoln Financial Group (NYSE: LNC), Lead Director for Southwest Airlines (NYSE: LUV), and the John Hancock Mutual Funds Board. He has also previously served on the boards of more than a dozen other public and private companies, including as Chairman of the Board of GloFish LLC. His many honors include a Distinguished Alumnus Award from Michigan State University, from which he also received an honorary law degree and the Distinguished Service Award from UT Austin. Dr. Cunningham received a Bachelor of Business Administration in 1966, a Master of Business Administration in 1967, and a doctorate in 1971, each from Michigan State University.
David Shockley, Jr.
H. David Shockley, Jr. is the Founder and Chief Executive Officer of International Biophysics Corporation (IBC), a 30-year-old medical device development and manufacturing company based in Austin, Texas. He is also the Founder and Chairman of the Board of Organicare, a pharmaceutical drug developer and manufacturer in Austin. Mr. Shockley and IBC have developed many products over the past three decades, with several of these products becoming “spinoff” companies that were ultimately sold. In total, Mr. Shockley has been involved with the sale of more than $125 million in businesses that he started. He began his career in 1988 at Cardio Metrics, where he rose to President prior to its $3 million sale. In addition to serving as Chairman of Organicare, Mr. Shockley is currently serving as a Board Member for Safen Medical Devices, and he formerly served as a Director for numerous other health-related companies that were successfully sold. Mr. Shockley attended the University of Texas at Austin, where he received a Bachelor of Science in biology.
Mr. Joe Aragona is a Co-Founder and General Partner of Austin Ventures – an Austin, Texas-based venture capital and private equity firm which has invested $4 billion in more than 375 companies since 1982. His investing experience ranges from early stage to middle market recapitalizations and spans a broad range of industries, including technology, industrial products, and financial services. Mr. Aragona received his Master of Business Administration from Harvard Business School and his Bachelor of Arts from Harvard University. He served on the Board of Directors of the National Venture Capital Association (NVCA) from 1999-2006 and is a former Chairman. Mr. Aragona is currently Vice Chair of the Board of Directors of the LiveSTRONG Foundation, which empowers people affected by cancer, and Casa Montessori, an early childhood development center. Mr. Aragona is currently investing through his family office while he serves as an Adviser and Limited Partner to two of the Austin Ventures next-generation endeavors: AV Capital – a middle-market private equity group; and AVX – a software-focused early-stage investment group.
Mr. Jason Dorsey is a generational researcher, strategist and bestselling author. Mr. Dorsey is Co-Founder and President of The Center for Generational Kinetics (CGK), the premier Gen Z and Millennial research and insights firm. CGK has led more than 65 generational studies around the world and made the Inc. 5000, twice. CGK’s clients include numerous Fortune 500 companies in health care, manufacturing and technology. Mr. Dorsey has been featured as a generational expert on more than 200 TV interviews and was called a “research guru” by Adweek. His forthcoming book is Zconomy: How Gen Z Will Change the Future of Business. Mr. Dorsey has served on the Board of Directors at both public and private technology companies, including Ultimate Software Group, which was acquired for $11 billion in 2019. Mr. Dorsey’s advisory work with Nuclein includes helping with overall strategy, marketing and external communications.
The Nuclein advisory board provides expertise in fields including biotechnology, regulatory, fast-growth enterprises, marketing, and communications.
Dr. Ronny Ginor
Dr. Ronny Ginor is a Venture Partner with OrbiMed and has been active in the life science industry for more than 20 years, with an emphasis on drug delivery platforms, vascular medicine, oncology, and regulatory strategies. Most recently, Dr. Ginor served as CEO of Becker & Associates Consulting, an FDA consulting firm that was acquired by a multinational corporation in 2012. Dr. Ginor served in the Israeli Defense Forces Unit 8200 prior to earning undergraduate and medical degrees from George Washington University. He trained at Memorial Sloan Kettering Cancer Center in New York and published on three-dimensional conformal radiation therapy of the prostate. He performed an acting internship at Stanford, where he focused on Non-Hodgkin lymphoma. Dr. Ginor has patented technologies related to breast cancer, thyroid disease and cardiology.
Mr. Alan Richey currently serves as Senior Vice President for Dell Technologies where he leads Dell’s Global Products, Operations and Solutions Legal teams. Mr. Richey brings to the Advisory Board a broad network and expertise in intellectual property support, supply chain strategy and management, international distribution, manufacturing, regulatory, trade compliance and logistics. Prior to joining Dell, Mr. Richey was Associate General Counsel for Micron Technology where he was responsible for providing support for Micron’s global manufacturing and product organizations. He also served as an associate for Gibson, Dunn & Crutcher, where his practice focused on business litigation and commercial matters. Mr. Richey earned a JD and graduated Magna Cum Laude from the University of Houston, an MBA from Southwestern Oklahoma State University, and a Bachelor of Science in Accounting from Cameron University. In addition to his law license, Mr. Richey is a certified public accountant and serves on various commercial and not-for-profit boards.
Mr. Chris Turner is an award-winning entrepreneur who has led two business ventures onto Inc Magazine’s list of Fastest Growing Privately Held Companies. Mr. Turner serves as CEO and Co-Founder of StampedeConsulting.com, a firm that operationalizes large-scale outside sales and market research programs. Mr. Turner has been featured in numerous national and international interviews via Fox News, BBC Radio, Campaigns & Elections, and more. Mr. Turner was awarded his Bachelor of Arts from the University of Texas at Austin after only two years of study, 1990-1992, and subsequently received his Master of Arts in comparative politics from the Albert-Ludwigs University in Freiburg, Germany. Mr. Turner’s advisory work with Nuclein will focus on global strategy, market positioning and governmental affairs.